OCULAR THERAPEUTIX, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.84 USD | +1.57% |
|
-0.51% | +30.94% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 189.9 | 1,559 | 534 | 216.4 | 491.6 | 890.6 | - | - |
| Enterprise Value (EV) 1 | 189.9 | 1,380 | 421.2 | 168.1 | 491.6 | 890.6 | 890.6 | 890.6 |
| P/E ratio | -2.07 x | -8.09 x | -77.4 x | -2.9 x | -4.42 x | -5.71 x | -6.89 x | -7.14 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 44.9 x | 89.6 x | 12.3 x | 4.2 x | 8.41 x | 13.4 x | 11.3 x | 7.1 x |
| EV / Revenue | 44.9 x | 89.6 x | 12.3 x | 4.2 x | 8.41 x | 13.4 x | 11.3 x | 7.1 x |
| EV / EBITDA | -2.28 x | -25.9 x | -7.06 x | -2.83 x | -6.19 x | -7.81 x | 0.31 x | -56.4 x |
| EV / FCF | -2.38 x | -28.7 x | -8 x | -3.42 x | -6.44 x | -9.9 x | -9.73 x | -13.3 x |
| FCF Yield | -42% | -3.49% | -12.5% | -29.3% | -15.5% | -10.1% | -10.3% | -7.52% |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 48,080 | 75,302 | 76,610 | 77,010 | 110,219 | 154,889 | - | - |
| Reference price 2 | 3.950 | 20.70 | 6.970 | 2.810 | 4.460 | 5.750 | 5.750 | 5.750 |
| Announcement Date | 12/03/20 | 11/03/21 | 28/02/22 | 06/03/23 | 11/03/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 4.227 | 17.4 | 43.52 | 51.49 | 58.44 | 66.29 | 78.82 | 125.5 |
| EBITDA 1 | -83.27 | -60.07 | -75.62 | -76.54 | -79.4 | -114 | 2,889 | -15.79 |
| EBIT 1 | -85.8 | -62.85 | -78.04 | -78.65 | -82.38 | -117.4 | -116.5 | -102.7 |
| Operating Margin | -2,029.86% | -361.13% | -179.3% | -152.74% | -140.96% | -177.03% | -147.84% | -81.85% |
| Earnings before Tax (EBT) 1 | -86.37 | -155.6 | -6.553 | -71.04 | -80.74 | -144.6 | -118.4 | -98.13 |
| Net income 1 | -86.37 | -155.6 | -6.553 | -71.04 | -80.74 | -136.1 | -114.3 | -97.16 |
| Net margin | -2,043.34% | -894.31% | -15.06% | -137.95% | -138.14% | -205.3% | -144.98% | -77.41% |
| EPS 2 | -1.910 | -2.560 | -0.0900 | -0.9700 | -1.010 | -1.007 | -0.8343 | -0.8050 |
| Free Cash Flow 1 | -79.82 | -54.4 | -66.74 | -63.32 | -76.32 | -90 | -91.5 | -67 |
| FCF margin | -1,888.24% | -312.56% | -153.36% | -122.96% | -130.59% | -135.76% | -116.09% | -53.38% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 12/03/20 | 11/03/21 | 28/02/22 | 06/03/23 | 11/03/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 12.31 | 13.19 | 12.27 | 11.96 | 14.08 | 13.37 | 15.19 | 15.08 | 14.8 | 14.77 | 15.91 | 16.76 | 18.25 | 18.49 | 18.83 |
| EBITDA 1 | -17.48 | -17.28 | - | -21.04 | -18.87 | -22.07 | -19.92 | -18.32 | - | - | -29.19 | -27.6 | -26.5 | -25.82 | -25.82 |
| EBIT 1 | -18.05 | -17.83 | -19.92 | -21.54 | -19.36 | -22.55 | -20.57 | -19.21 | -20.05 | -31.62 | -27.58 | -28.88 | -32.57 | -23.03 | -23.72 |
| Operating Margin | -146.63% | -135.23% | -162.37% | -180.06% | -137.55% | -168.6% | -135.45% | -127.41% | -135.45% | -214% | -173.35% | -172.29% | -178.47% | -124.52% | -126.02% |
| Earnings before Tax (EBT) 1 | -3.85 | -12.54 | -18.77 | -24.19 | -15.54 | -30.32 | -20.68 | -0.516 | -29.22 | -64.85 | -27.49 | -28.58 | -32.62 | -23.21 | -23.92 |
| Net income 1 | -3.85 | -12.54 | -18.77 | -24.19 | -15.54 | -30.32 | -20.68 | -0.516 | -29.22 | -64.85 | -26.68 | -27.83 | -26.93 | -23.21 | -23.92 |
| Net margin | -31.28% | -95.11% | -152.99% | -202.16% | -110.41% | -226.69% | -136.19% | -3.42% | -197.41% | -438.93% | -167.7% | -166.02% | -147.55% | -125.52% | -127.08% |
| EPS 2 | -0.0500 | -0.1600 | -0.2400 | -0.3100 | -0.2400 | -0.3900 | -0.2600 | -0.0100 | -0.3500 | -0.4900 | -0.2017 | -0.2150 | -0.2367 | -0.1600 | -0.1600 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 28/02/22 | 09/05/22 | 08/08/22 | 07/11/22 | 06/03/23 | 08/05/23 | 07/08/23 | 07/11/23 | 11/03/24 | 07/05/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | 179 | 113 | 48.3 | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -79.8 | -54.4 | -66.7 | -63.3 | -76.3 | -90 | -91.5 | -67 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | -53% | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share 2 | - | - | - | - | -0.8200 | 0.0700 | 0.0800 | - |
| Capex 1 | 2.24 | 0.84 | 1.19 | 3.72 | 6.09 | 10 | 6.48 | 6.48 |
| Capex / Sales | 52.95% | 4.83% | 2.74% | 7.21% | 10.42% | 15.08% | 8.22% | 5.16% |
| Announcement Date | 12/03/20 | 11/03/21 | 28/02/22 | 06/03/23 | 11/03/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
5.75
USD
Average target price
14.5
USD
Spread / Average Target
+152.17%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +30.94% | 891M | |
| +32.36% | 698B | |
| +26.51% | 568B | |
| -4.40% | 358B | |
| +19.46% | 328B | |
| +3.50% | 283B | |
| +16.34% | 238B | |
| +6.68% | 203B | |
| -9.08% | 198B | |
| +8.62% | 165B |
- Stock Market
- Equities
- OCUL Stock
- Financials Ocular Therapeutix, Inc.
